bispecifics

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

Antibody engineering drives therapeutic innovation. Biointron advances bispecific design, Fc optimization, and humanization to enhance potency, reduce risks, and accelerate development.

Explore next‑generation antibody formats—bispecifics, trispecifics, and modular designs—that unlock new mechanisms, sharpen targeting, and raise the bar for developability.